Reviewing bluebird bio (BLUE) & Curis (CRIS)

bluebird bio (NASDAQ:BLUE) and Curis (NASDAQ:CRIS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares bluebird bio and Curis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
bluebird bio -1,326.02% -31.50% -26.59%
Curis -316.98% -299.20% -59.60%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for bluebird bio and Curis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bluebird bio 1 9 15 0 2.56
Curis 0 0 3 0 3.00

bluebird bio presently has a consensus price target of $209.74, suggesting a potential upside of 58.39%. Curis has a consensus price target of $19.00, suggesting a potential upside of 1,037.72%. Given Curis’ stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than bluebird bio.

Institutional & Insider Ownership

98.6% of bluebird bio shares are held by institutional investors. Comparatively, 33.5% of Curis shares are held by institutional investors. 3.0% of bluebird bio shares are held by insiders. Comparatively, 4.3% of Curis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

bluebird bio has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Curis has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Earnings & Valuation

This table compares bluebird bio and Curis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
bluebird bio $35.43 million 204.40 -$335.64 million ($7.71) -17.18
Curis $9.90 million 5.59 -$53.31 million ($1.80) -0.93

Curis has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

About bluebird bio

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

About Curis

Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply